<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33037138</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>12</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1538-8514</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>20</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Molecular cancer therapeutics</Title>
          <ISOAbbreviation>Mol Cancer Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer.</ArticleTitle>
        <Pagination>
          <StartPage>150</StartPage>
          <EndPage>160</EndPage>
          <MedlinePgn>150-160</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1158/1535-7163.MCT-19-0911</ELocationID>
        <Abstract>
          <AbstractText>Pancreatic ductal adenocarcinoma (PDAC) has a prominent fibrotic stroma, which is a result of interactions between tumor, immune and pancreatic stellate cells (PSC), or cancer-associated fibroblasts (CAF). Targeting inflammatory pathways present within the stroma may improve access of effector immune cells to PDAC and response to immunotherapy. Heat shock protein-90 (Hsp90) is a chaperone protein and a versatile target in pancreatic cancer. Hsp90 regulates a diverse array of cellular processes of relevance to both the tumor and the immune system. However, to date the role of Hsp90 in PSC/CAF has not been explored in detail. We hypothesized that Hsp90 inhibition would limit inflammatory signals, thereby reprogramming the PDAC tumor microenvironment to enhance sensitivity to PD-1 blockade. Treatment of immortalized and primary patient PSC/CAF with the Hsp90 inhibitor XL888 decreased IL6, a key cytokine that orchestrates immune changes in PDAC at the transcript and protein level <i>in vitro</i> XL888 directly limited PSC/CAF growth and reduced Jak/STAT and MAPK signaling intermediates and alpha-SMA expression as determined via immunoblot. Combined therapy with XL888 and anti-PD-1 was efficacious in C57BL/6 mice bearing syngeneic subcutaneous (Panc02) or orthotopic (KPC-Luc) tumors. Tumors from mice treated with both XL888 and anti-PD-1 had a significantly increased CD8<sup>+</sup> and CD4<sup>+</sup> T-cell infiltrate and a unique transcriptional profile characterized by upregulation of genes associated with immune response and chemotaxis. These data demonstrate that Hsp90 inhibition directly affects PSC/CAF <i>in vitro</i> and enhances the efficacy of anti-PD-1 blockade <i>in vivo</i>.</AbstractText>
          <CopyrightInformation>©2020 American Association for Cancer Research.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yuchen</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-9066-8658</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ware</LastName>
            <ForeName>Michael B</ForeName>
            <Initials>MB</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zaidi</LastName>
            <ForeName>Mohammad Y</ForeName>
            <Initials>MY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Winship Cancer Institute of Emory University, Atlanta, Georgia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ruggieri</LastName>
            <ForeName>Amanda N</ForeName>
            <Initials>AN</Initials>
            <Identifier Source="ORCID">0000-0003-1005-9607</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Olson</LastName>
            <ForeName>Brian M</ForeName>
            <Initials>BM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Komar</LastName>
            <ForeName>Hannah</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Farren</LastName>
            <ForeName>Matthew R</ForeName>
            <Initials>MR</Initials>
            <Identifier Source="ORCID">0000-0001-5510-8869</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nagaraju</LastName>
            <ForeName>Ganji Purnachandra</ForeName>
            <Initials>GP</Initials>
            <Identifier Source="ORCID">0000-0002-4989-5234</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Chao</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0002-9066-8658</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Biostatistics, Winship Cancer Institute of Emory University, Atlanta, Georgia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Zhengjia</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Epidemiology and Biostatistics, University of Illinois at Chicago, Chicago, Illinois.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sarmiento</LastName>
            <ForeName>Juan M</ForeName>
            <Initials>JM</Initials>
            <Identifier Source="ORCID">0000-0002-1874-6658</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Winship Cancer Institute of Emory University, Atlanta, Georgia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ahmed</LastName>
            <ForeName>Rafi</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Emory Vaccine Center, Atlanta, Georgia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maithel</LastName>
            <ForeName>Shishir K</ForeName>
            <Initials>SK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Winship Cancer Institute of Emory University, Atlanta, Georgia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>El-Rayes</LastName>
            <ForeName>Bassel F</ForeName>
            <Initials>BF</Initials>
            <Identifier Source="ORCID">0000-0002-2661-5746</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia. gregory.b.lesinski@emory.edu bassel.el-rayes@emoryhealthcare.org.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lesinski</LastName>
            <ForeName>Gregory B</ForeName>
            <Initials>GB</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia. gregory.b.lesinski@emory.edu bassel.el-rayes@emoryhealthcare.org.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P30 CA138292</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA228406</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Mol Cancer Ther</MedlineTA>
        <NlmUniqueID>101132535</NlmUniqueID>
        <ISSNLinking>1535-7163</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053961">Azabicyclo Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018841">HSP90 Heat-Shock Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010795">Phthalic Acids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C559121">XL 888</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053961" MajorTopicYN="N">Azabicyclo Compounds</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072645" MajorTopicYN="N">Cancer-Associated Fibroblasts</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D021441" MajorTopicYN="N">Carcinoma, Pancreatic Ductal</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018841" MajorTopicYN="N">HSP90 Heat-Shock Proteins</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010190" MajorTopicYN="N">Pancreatic Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058954" MajorTopicYN="N">Pancreatic Stellate Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010795" MajorTopicYN="N">Phthalic Acids</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061026" MajorTopicYN="N">Programmed Cell Death 1 Receptor</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>10</Day>
          <Hour>5</Hour>
          <Minute>29</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33037138</ArticleId>
        <ArticleId IdType="mid">NIHMS1635965</ArticleId>
        <ArticleId IdType="pmc">PMC7790996</ArticleId>
        <ArticleId IdType="doi">10.1158/1535-7163.MCT-19-0911</ArticleId>
        <ArticleId IdType="pii">1535-7163.MCT-19-0911</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin
2020;70(1):7–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31912902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res
2014;74(11):2913–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24840647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, et al.
Stromal biology and therapy in pancreatic cancer. Gut
2011;60(6):861–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20966025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Apte MV, Haber PS, Applegate TL, Norton ID, McCaughan GW, Korsten MA, et al.
Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture. Gut
1998;43(1):128–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1727174</ArticleId>
            <ArticleId IdType="pubmed">9771417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krizhanovsky V, Yon M, Dickins RA, Hearn S, Simon J, Miething C, et al.
Senescence of activated stellate cells limits liver fibrosis. Cell
2008;134(4):657–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3073300</ArticleId>
            <ArticleId IdType="pubmed">18724938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lonardo E, Frias-Aldeguer J, Hermann PC, Heeschen C. Pancreatic stellate cells form a niche for cancer stem cells and promote their self-renewal and invasiveness. Cell Cycle
2012;11(7):1282–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22421149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waghray M, Yalamanchili M, di Magliano MP, Simeone DM. Deciphering the role of stroma in pancreatic cancer. Curr Opin Gastroen
2013;29(5):537–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4112589</ArticleId>
            <ArticleId IdType="pubmed">23892539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SG, Hoadley KA, et al.
Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nature Genetics
2015;47(10):1168–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4912058</ArticleId>
            <ArticleId IdType="pubmed">26343385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, et al.
Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med
2017; 214(3):579–596.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5339682</ArticleId>
            <ArticleId IdType="pubmed">28232471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biffi G, Oni TE, Spielman B, Hao Y, Elyada E, Park Y, et al.
IL1-Induced JAK/STAT Signaling Is Antagonized by TGFbeta to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma. Cancer Discov
2019;9(2):282–301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6368881</ArticleId>
            <ArticleId IdType="pubmed">30366930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bressy C, Lac S, Nigri J, Leca J, Roques J, Lavaut MN, et al.
LIF Drives Neural Remodeling in Pancreatic Cancer and Offers a New Candidate Biomarker. Cancer Res
2018;78(4):909–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29269518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mace TA, Ameen Z, Collins A, Wojcik S, Mair M, Young GS, et al.
Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res
2013;73(10):3007–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3785672</ArticleId>
            <ArticleId IdType="pubmed">23514705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi Y, Gao W, Lytle NK, Huang P, Yuan X, Dann AM, et al.
Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Nature
2019;569(7754):131–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6565370</ArticleId>
            <ArticleId IdType="pubmed">30996350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang MT, Fer N, Galeas J, Collisson EA, Kim SE, Sharib J, et al.
Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer. Nat Commun
2019;10(1):3055.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6624260</ArticleId>
            <ArticleId IdType="pubmed">31296870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taipale M, Jarosz DF, Lindquist S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol
2010;11(7):515–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20531426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graner MW. HSP90 and Immune Modulation in Cancer. Adv Cancer Res
2016;129:191–224.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26916006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haggerty TJ, Dunn IS, Rose LB, Newton EE, Pandolfi F, Kurnick JT. Heat shock protein-90 inhibitors enhance antigen expression on melanomas and increase T cell recognition of tumor cells. PLoS One
2014;9(12):e114506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4264751</ArticleId>
            <ArticleId IdType="pubmed">25503774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rao A, Taylor JL, Chi-Sabins N, Kawabe M, Gooding WE, Storkus WJ. Combination therapy with HSP90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic T cells. Cancer Res
2012;72(13):3196–206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3389149</ArticleId>
            <ArticleId IdType="pubmed">22552283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, et al.
PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med
2014;211(5):781–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4010891</ArticleId>
            <ArticleId IdType="pubmed">24778419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagaraju GP, Park W, Wen J, Mahaseth H, Landry J, Farris AB, et al.
Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1alpha and STAT-3. Angiogenesis
2013;16(4):903–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23838996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bussenius J, Blazey CM, Aay N, Anand NK, Arcalas A, Baik T, et al.
Discovery of XL888: a novel tropane-derived small molecule inhibitor of HSP90. Bioorg Med Chem Lett
2012;22(17):5396–404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22877636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neckers L, Blagg B, Haystead T, Trepel JB, Whitesell L, Picard D. Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development. Cell Stress Chaperones
2018;23(4):467–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6045531</ArticleId>
            <ArticleId IdType="pubmed">29392504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pedersen KS, Kim GP, Foster NR, Wang-Gillam A, Erlichman C, McWilliams RR. Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study. Invest New Drugs
2015;33(4):963–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4905857</ArticleId>
            <ArticleId IdType="pubmed">25952464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma Y, Hwang RF, Logsdon CD, Ullrich SE. Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer. Cancer Res
2013;73(13):3927–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3702652</ArticleId>
            <ArticleId IdType="pubmed">23633481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Komar HM, Serpa G, Kerscher C, Schwoegl E, Mace TA, Jin M, et al.
Inhibition of Jak/STAT signaling reduces the activation of pancreatic stellate cells in vitro and limits caerulein-induced chronic pancreatitis in vivo. Sci Rep
2017;7(1):1787.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5431930</ArticleId>
            <ArticleId IdType="pubmed">28496202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol
2010;185(4):2273–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2923483</ArticleId>
            <ArticleId IdType="pubmed">20644162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mace TA, Shakya R, Pitarresi JR, Swanson B, McQuinn CW, Loftus S, et al.
IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut
2016; 67(2):320–332.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5406266</ArticleId>
            <ArticleId IdType="pubmed">27797936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McQuin C, Goodman A, Chernyshev V, Kamentsky L, Cimini BA, Karhohs KW, et al.
CellProfiler 3.0: Next-generation image processing for biology. PLoS Biol
2018;16(7):e2005970.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6029841</ArticleId>
            <ArticleId IdType="pubmed">29969450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lamprecht MR, Sabatini DM, Carpenter AE. CellProfiler: free, versatile software for automated biological image analysis. Biotechniques
2007;42(1):71–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17269487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bankhead P, Loughrey MB, Fernandez JA, Dombrowski Y, McArt DG, Dunne PD, et al.
QuPath: Open source software for digital pathology image analysis. Sci Rep
2017;7(1):16878.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5715110</ArticleId>
            <ArticleId IdType="pubmed">29203879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adachi S, Yasuda I, Nakashima M, Yamauchi T, Yamauchi J, Natsume H, et al.
HSP90 inhibitors induce desensitization of EGF receptor via p38 MAPK-mediated phosphorylation at Ser1046/1047 in human pancreatic cancer cells. Oncol Rep
2010;23(6):1709–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20428829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moser C, Lang SA, Hackl C, Wagner C, Scheiffert E, Schlitt HJ, et al.
Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer. Anticancer Res
2012;32(7):2551–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22753713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagaraju GP, Mezina A, Shaib WL, Landry J, El-Rayes BF. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib. Eur J Cancer
2016;52:109–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26682870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagaraju GP, Wu C, Merchant N, Chen Z, Lesinski GB, El-Rayes BF. Epigenetic effects of inhibition of heat shock protein 90 (HSP90) in human pancreatic and colon cancer. Cancer Lett
2017;402:110–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28583846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagaraju GP, Zakka KM, Landry JC, Shaib WL, Lesinski GB, El-Rayes BF. Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer. Int J Cancer
2019;145(6):1529–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30801702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song D, Chaerkady R, Tan AC, Garcia-Garcia E, Nalli A, Suarez-Gauthier A, et al.
Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer. Mol Cancer Ther
2008;7(10):3275–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18852131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xue N, Jin J, Liu D, Yan R, Zhang S, Yu X, et al.
Antiproliferative effect of HSP90 inhibitor Y306zh against pancreatic cancer is mediated by interruption of AKT and MAPK signaling pathways. Curr Cancer Drug Targets
2014;14(7):671–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25219422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang T, Hamza A, Cao X, Wang B, Yu S, Zhan CG, et al.
A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther
2008;7(1):162–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18202019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blair AB, Kim VM, Muth ST, Saung MT, Lokker N, Blouw B, et al.
Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer. Clin Cancer Res
2019; 25(17):5351–5363.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6726532</ArticleId>
            <ArticleId IdType="pubmed">31186314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fearon DT. The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance. Cancer Immunol Res
2014;2(3):187–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24778314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, et al.
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci USA
2013;110(50):20212–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3864274</ArticleId>
            <ArticleId IdType="pubmed">24277834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lo A, Wang LC, Scholler J, Monslow J, Avery D, Newick K, et al.
Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells. Cancer Res
2015;75(14):2800–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4506263</ArticleId>
            <ArticleId IdType="pubmed">25979873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mace TA, Bloomston M, Lesinski GB. Pancreatic cancer-associated stellate cells: A viable target for reducing immunosuppression in the tumor microenvironment. Oncoimmunology
2013;2(7):e24891.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3782129</ArticleId>
            <ArticleId IdType="pubmed">24073373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bae J, Munshi A, Li C, Samur M, Prabhala R, Mitsiades C, et al.
Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells. J Immunol
2013;190(3):1360–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3819808</ArticleId>
            <ArticleId IdType="pubmed">23293352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trojandt S, Reske-Kunz AB, Bros M. Geldanamycin-mediated inhibition of heat shock protein 90 partially activates dendritic cells, but interferes with their full maturation, accompanied by impaired upregulation of RelB. J Exp Clin Cancer Res
2014;33:16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3926270</ArticleId>
            <ArticleId IdType="pubmed">24524692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schnaider T, Somogyi J, Csermely P, Szamel M. The Hsp90-specific inhibitor, geldanamycin, blocks CD28-mediated activation of human T lymphocytes. Life Sci
1998;63(11):949–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9747895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kelly PN. CD28 is a critical target for PD-1 blockade. Science
2017;355(6332):1386.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28360298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamphorst AO, Wieland A, Nasti T, Yang S, Zhang R, Barber DL, et al.
Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science
2017;355(6332):1423–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5595217</ArticleId>
            <ArticleId IdType="pubmed">28280249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Proia DA, Kaufmann GF. Targeting Heat-Shock Protein 90 (HSP90) as a Complementary Strategy to Immune Checkpoint Blockade for Cancer Therapy. Cancer Immunol Res
2015;3(6):583–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25948551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mbofung RM, McKenzie JA, Malu S, Zhang M, Peng W, Liu C, et al.
HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. Nat Commun
2017;8(1):451.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5587668</ArticleId>
            <ArticleId IdType="pubmed">28878208</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
